Court rules SEBI lacked authority in scheme petitions under Companies Act, 1956. Valuation upheld, SEBI's claims dismissed.

The court held that SEBI lacked the authority to intervene in scheme petitions under Sections 391-394 of the Companies Act, 1956. It dismissed SEBI's applications, ruling that there was no fraud or suppression of material facts. The court found the valuation and swap ratio justified, emphasizing shareholder approval and the adequacy of disclosures. The court highlighted the acceptance of the DCF method for valuation and upheld the actions of the parties involved, dismissing SEBI's claims and ordering costs against SEBI.

---

---

Issues Involved:
1. Locus of SEBI in scheme petitions under Sections 391-394 of the Companies Act, 1956.
2. Alleged suppression of material facts by the petitioner.
3. Alleged violation of Accounting Standards in valuation.
4. Alleged fraud on shareholders by overvaluation of assets.
5. Justification of the swap ratio in the 2011 Composite Scheme.
6. Validity of the valuation method adopted by Grant Thornton.
7. Disclosure of financial projections and data provided to the valuer.
8. Infusion of additional share capital in Ikisan by promoters.
9. Alleged unjustified valuation of assets by DCF method.

Detailed Analysis:

1. Locus of SEBI in Scheme Petitions:
The court examined whether SEBI has the locus to intervene in scheme petitions under Sections 391-394 of the Companies Act, 1956. It was held that SEBI does not have locus to intervene in such matters, as established by the Division Bench in the Sterlite case. The court noted that SEBI's powers under the SEBI Act do not override the provisions of the Companies Act regarding scheme petitions. The court also emphasized that SEBI did not act on a shareholder's complaint before the scheme was sanctioned, which further undermines its locus.

2. Alleged Suppression of Material Facts:
SEBI alleged that the petitioner suppressed material facts, including the valuation report and financial projections. The court found that all necessary disclosures were made to the shareholders, stock exchanges, Regional Director, and Official Liquidator. The valuation report was available for inspection, and the shareholders approved the scheme with a significant majority. The court concluded that there was no suppression of material facts.

3. Alleged Violation of Accounting Standards:
SEBI contended that the valuation of intangible assets in Ikisan's balance sheet violated Accounting Standards 14 and 26. The court held that the valuation was consistent with AS-14, which allows for assets to be recorded at fair value. The court also noted that even if there were deviations from accounting standards, it would not justify setting aside the scheme, as accounting takes place after the transaction and does not change its character.

4. Alleged Fraud on Shareholders:
SEBI argued that the valuation of Ikisan's assets was inflated, constituting a fraud on the shareholders. The court found no evidence of fictitious assets or overvaluation. It was noted that the valuation was based on future projections and the potential of the business, which is a recognized method. The court emphasized that valuation is not an exact science and differences in expert opinions do not constitute fraud.

5. Justification of the Swap Ratio:
SEBI challenged the swap ratio, arguing that it was unjustified given the financial condition of Ikisan. The court upheld the swap ratio, noting that it was based on the DCF method, which is appropriate for valuing businesses with future growth potential. The court also highlighted that the shareholders approved the scheme, indicating their acceptance of the swap ratio.

6. Validity of the Valuation Method:
SEBI contended that the valuation method adopted by Grant Thornton was flawed. The court found that the DCF method is a widely accepted and appropriate method for valuing businesses with future potential. The court noted that Grant Thornton reviewed the data for consistency and reasonableness and did not accept the projections at face value.

7. Disclosure of Financial Projections:
SEBI alleged that the petitioner refused to disclose financial projections provided to the valuer. The court held that companies are not required to disclose such projections in scheme matters, as they are considered confidential and price-sensitive. The court noted that the valuation report was available for inspection by shareholders, who approved the scheme.

8. Infusion of Additional Share Capital:
SEBI argued that the promoters infused additional share capital in Ikisan to gain more shares in NFCL. The court found that the infusion was for setting up a micro-irrigation plant and was not intended to manipulate share allotment. The court noted that the swap ratio was based on projected cash flows and not the additional capital.

9. Alleged Unjustified Valuation by DCF Method:
SEBI contended that the DCF method used for valuation was unjustified. The court upheld the use of the DCF method, noting that it appropriately considers future cash flows and growth potential. The court emphasized that the method is recognized and accepted in valuation exercises.

Conclusion:
The court dismissed SEBI's applications, holding that SEBI failed to establish any fraud or suppression of material facts. The court found that the valuation and swap ratio were justified and that all necessary disclosures were made. The court emphasized the importance of respecting the commercial wisdom of shareholders who approved the scheme. The applications were dismissed with costs.

---